Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Crucell   /   RT Dinsdag 29 augustus - 2006

Crucell« Terug naar discussie overzicht

RT Dinsdag 29 augustus - 2006

Volgen
255 Posts
Pagina: 1 2 3 4 5 6 ... 13 »» | Laatste | Omlaag ↓
  1. [verwijderd] 29 augustus 2006 06:28
    Goede morgen Crucellers,

    Gisteren weer een “saai “ dagje. Zoals zo vele keren was de koers in de eerste handels uren (en het volume) amper van zijn plaats te brengen. Op het forum sloeg zowat de verveling toe.
    Maar later in de middag begon de kentering. De koers ging naar beneden en het volume nam naar verhouding flink toe. Mijns inziens geen best teken. (ook volgens TA aanhangers?).

    Er zijn diverse berichten geplaatst aangaande analisten verwachtingen. Ik zal ze niet herhalen.
    Zie o.a. dagdraad van gisteren. Wat echter opvalt, is de enorme diversiteit in de verwachtingen. We praten niet over enkele procenten verschil tussen minima en maxima verwachtingen, maar tussen velen tientallen zo niet meer dan 100% verschil tussen hoog-laag verwachtingen.

    Wie moeten we nu geloven? Blijkbaar “weten” de analisten het ook niet en “gokken” sommige maar. Ik geloof echt niet dat hier redelijke calculaties ten grondslag liggen.
    De meningen, en aannames liggen simpelweg te ver uiteen.

    Hetzelfde zie je hier op het forum, van hosanna, tot diepe mineur. Nog even en de “waarheid” komt boven tafel. Velen al anticiperend op dit moment hun posities ingenomen c.q. afgebouwd. Wat mij persoonlijk betreft, ik laat het allemaal maar over mij heen komen.

    De meningen op dit forum lopen van 1 cent (flip flap/yellowww) tot 1000 euro of meer (trudy etc. in 2010 of wat eerder komt). Het zal wel. Gewoon rustig blijven zitten en niet in paniek raken. Mocht de koers plotseling een dip naar beneden vertonen, dan (weer) een goed aankoopmoment? En als het omhoog gaat, bevestiging dat we toch een goed aandeel in handen hebben? Wie zal het zeggen. Vandaag wordt een dag van huilen of lachen.

    De resultaten:

    Amsterdam:

    CRUCELL (CRXL:AMS) 16,57 (-1,07%)
    Koersgegevens
    Laatste 16,57 Volume 299.209
    Verschil -0,18 Verschil% -1,07%
    Bied 16,56 Laat 16,59
    Aantal Bieden 1.400 Aantal Laten 7.984
    Dag hoog 16,90 Dag laag 16,52
    Open 16,89 Slotkoers 16,75

    Tickliste gaf geen “rare” (top)deals aan:
    Zeit…… Kurs… Volumen
    9:03:51 16,80 10000
    17:30:12 16,57 5000
    9:11:37 16,72 5000
    17:30:12 16,57 3771
    16:09:33 16,53 3125
    17:30:12 16,57 3000
    16:27:34 16,65 2409
    15:40:34 16,65 2381
    17:30:12 16,57 2301
    17:22:27 16,57 2000
    16:22:46 16,60 2000
    15:40:46 16,60 1989
    15:23:02 16,73 1954
    16:54:24 16,60 1856
    15:23:16 16,73 1842
    17:30:13 16,57 1713
    17:30:13 16,57 1600
    17:30:13 16,57 1500
    16:26:03 16,65 1500
    15:40:05 16,65 1500
    15:02:35 16,69 1500
    14:59:45 16,70 1500
    15:44:52 16,58 1486
    17:06:53 16,61 1361
    16:00:12 16,58 1300
    14:58:08 16,70 1300
    16:54:53 16,60 1292
    12:28:10 16,76 1143
    12:27:16 16,78 1102

    VS:

    CRUCELL NV - ADS (CRXL:NAS) 21,20 (-1,17%)($21.20:1.2821 = euro 16.54)
    Koersgegevens
    Laatste 21,20 Volume 70.185
    Verschil -0,25 Verschil% -1,17%
    Bied 17,91 Laat 21,35
    Aantal Bieden 700 Aantal Laten 200
    Dag hoog 21,40 Dag laag 21,05
    Open 21,34 Slotkoers 21,45

    Afwachten maar.

    Zal Flosz de eerste zijn met de q2 cijfers?

    Hans
  3. [verwijderd] 29 augustus 2006 08:04
    29-08-2006 08:02:34 CRUCELL: OMZET 2eKW 2006 EUR 18,9 MLN; VERW. EUR 27,7 MLN
    CRUCELL ZIET NOG STEEDS CASH BURN 2006 EUR 33-38 MLN 08:03:03
    CRUCELL ZIET NOG STEEDS OMZET 2006 EUR 130-150 MLN 08:02:58
    CRUCELL: VERLIES 2eKW '06 EUR 25,7 MLN; VERW. EUR 16,7 MLN

    CRUCELL HERHAALT VERWACHTING BREAK EVEN IN 2007
  4. [verwijderd] 29 augustus 2006 08:07
    Published: 08:00 29.08.2006 GMT+2 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562

    Crucell Announces Second Quarter 2006 Results

    Leiden, The Netherlands, August 29, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, SWX: CRX) today announced its financial results for the first half-year ended June 30, 2006, based on International Financial Reporting Standards (IFRS).

    Total revenues for the second quarter were €18.9 million and other operating income was €2.8 million. Net loss for the second quarter of 2006 attributable to equity holders of the parent amounted to €25.7 million. Total revenues for the six months ended June 30, 2006, were €30.6 million; other operating income amounted to €4.8 million for the first six months of 2006. Net loss for the first six months of 2006 attributable to equity holders of the parent amounted to €40.4 million.

    Cash and cash equivalents were €177.7 million on June 30, 2006, compared to €178.7 million at the end of the first quarter. Proceeds from the sale of discontinued operations and a reclassification of short-term financial assets to cash, offset cash used in operations in the second quarter. Total assets on June 30, 2006, were €616.1 million.

    Crucell's Chief Financial Officer Leonard Kruimer said: "The second quarter results are in line with our expectations as they reflect the effects of purchase price allocation, one-time integration costs, and fully integrated R&D and SG&A costs. Product sales in our Berna subsidiary were up 9% over the same six-month period last year. Given the strong seasonal pattern of these sales, and the expected launch of Quinvaxem(TM), we reiterate our previous guidance for full-year revenue and cash burn: revenue, including other operating income, of €130 to €150 million, with 2006 operational cash burn in the range of €33 to €38 million."


    Operational Review Second Quarter 2006

    * Berna Biotech Acquisition: Crucell's offer for Berna Biotech AG was settled on February 22, 2006. The Company now holds 98.4% of all issued Berna shares. The Company is in the process of delisting the remaining shares, which is expected to be completed in the fourth quarter.

    * Quinvaxem: The Korea Food and Drug Administration (KFDA) awarded licensure to Quinvaxem(TM), a fully liquid pentavalent vaccine co-developed with Chiron Corporation, in March 2006. Crucell has started production of the vaccine in Korea and first shipments will be made once pre-qualification is received from the WHO.

    * Divestments: Crucell concluded the sale of Rhein Biotech GmbH and veterinary pharmaceuticals company Dr. E. Gräub AG. These divestments enabled Crucell to align its portfolio of activities with its strategic priorities. Total proceeds amounted to €15.4 million.

    * Avian influenza vaccine clinical trial: Crucell announced the start of a clinical trial, performed in collaboration with the University of Leicester, UK, testing three types of vaccines against the H9N2 avian influenza virus in humans. The trial involves the vaccination of 560 healthy adults, and will allow Crucell to choose the best vaccine modality for further clinical studies with pandemic flu vaccines. First results of the study are expected by the end of 2006.

    * Patent infringement: Crucell settled its patent infringement proceedings against CEVEC Pharmaceuticals GmbH. The final claim in the case was withdrawn following CEVEC's commitment not to use its cell bank in any way that would constitute further infringement of Crucell's European PER.C6® patent.

    * STAR(TM) Technology: Crucell signed a non-exclusive STAR(TM) research license agreement with Cambridge, Massachusetts-based Millennium Pharmaceuticals Corporation.

    * PER.C6® Licensing: Crucell secured new PER.C6® licensing deals with Upstate USA, BIOA&D and Immuno-Biological Laboratories during the second quarter.

    * PER.C6® R&D Center: Crucell and technology partner DSM Biologics announced the establishment of a new PER.C6® R&D Center in Cambridge, Massachusetts, and the appointment of Dr Marco Cacciuttolo as CEO. Operations are expected to commence by the end of 2006.

    * Supervisory Board: Mr. Pieter Strijkert, chairman of Crucell's Supervisory Board since the Company's incorporation, stepped down at the Annual General Meeting of Shareholders on June 2, 2006. He was succeeded by the vice-chairman of the Supervisory Board, Mr. Jan Oosterveld.

    * Suspension of Aerugen® clinical development: On July 18, 2006, the Company announced the suspension of the clinical development program for Aerugen®, a vaccine for the prevention of Pseudomonas aeruginosa infection.


    Details of the Financial Results First Half-Year

    Revenues and Other Operating Income
    Revenues for the first half-year of 2006 were €30.6 million, compared to €13.4 million in the same period last year. Revenues consist of product sales, license revenues and service fees. Revenues in 2006 represent product sales from Berna from the moment of acquisition at February 22, 2006; license revenues and service fees do not include sales from Berna and are therefore included for six months. Product revenues amount to €21.5 million, concentrated in pediatric and travel vaccines. Product revenues are seasonal and have historically been concentrated in the second half of the year. This is due to seasonal sales of influenza vaccine, and the projected sales of the new Quinvaxem(TM) pediatric vaccine. Comparable product sales from Berna in the first half-year 2006 were up 9% over same period last year.

    License revenues were €4.6 million, a decrease of €3.7 million over last year. Last year's license revenues included a €2 million milestone and a significant €2 million up-front fee from a partner. License revenue consisted of initial payments from new contracts as well as annual and other payments on existing contracts. Service fees amount to €4.5 million, compared to €5.1 million last year, which represents a slight decrease in chargeable development activities. Service fees represent revenues for product development activities performed under contracts with partners and licensees.

    Other Operating income was €4.8 million, compared to €2.6 million in the same period last year. Other operating income consists of government grants, which increased slightly to €3.0 million, and other income of €1.8 million.

    Cost of Goods Sold
    Cost of goods sold for the first six months of 2006 amounted to €27.4 million, €24.2 million of which represents product costs and the remainder of €3.2 million represents costs of service activities. The €24.2 million in product costs is relatively high since it includes a €6.4 million inventory purchase price allocation charge. The remaining step-up in inventory on June 30, 2006, as a result of the purchase price allocation, amounts to €11 million, which will be charged to cost of goods sold in future accounting periods.

    Expenses
    Total expenses consist of research and development (R&D) expenses and selling, general and administrative (SG&A) expenses. Total R&D and SG&A expenses were €48.6 for the first six months of 2006. That represents a €27.1 million increase over the same period last year. The difference is primarily attributable to combining activities of Crucell and Berna since acquisition.

    R&D expenses amounted to €29.8 million, which represents a €16.3 million increase over the first half of 2005. Berna clinical p
  5. [verwijderd] 29 augustus 2006 08:07
    Crucell Announces Second Quarter 2006 Results 1/2
    Source: cws.huginonline.com/C/132631/PR/20060...
    PDF: hugin.info/132631/R/1071967/183209.pdf


    Leiden, The Netherlands, August 29, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, SWX: CRX) today announced its financial results for the first half-year ended June 30, 2006, based on International Financial Reporting Standards (IFRS).

    Total revenues for the second quarter were €18.9 million and other operating income was €2.8 million. Net loss for the second quarter of 2006 attributable to equity holders of the parent amounted to €25.7 million. Total revenues for the six months ended June 30, 2006, were €30.6 million; other operating income amounted to €4.8 million for the first six months of 2006. Net loss for the first six months of 2006 attributable to equity holders of the parent amounted to €40.4 million.

    Cash and cash equivalents were €177.7 million on June 30, 2006, compared to €178.7 million at the end of the first quarter. Proceeds from the sale of discontinued operations and a reclassification of short-term financial assets to cash, offset cash used in operations in the second quarter. Total assets on June 30, 2006, were €616.1 million.

    Crucell's Chief Financial Officer Leonard Kruimer said: "The second quarter results are in line with our expectations as they reflect the effects of purchase price allocation, one-time integration costs, and fully integrated R&D and SG&A costs. Product sales in our Berna subsidiary were up 9% over the same six-month period last year. Given the strong seasonal pattern of these sales, and the expected launch of Quinvaxem(TM), we reiterate our previous guidance for full-year revenue and cash burn: revenue, including other operating income, of €130 to €150 million, with 2006 operational cash burn in the range of €33 to €38 million."


    Operational Review Second Quarter 2006

    * Berna Biotech Acquisition: Crucell's offer for Berna Biotech AG was settled on February 22, 2006. The Company now holds 98.4% of all issued Berna shares. The Company is in the process of delisting the remaining shares, which is expected to be completed in the fourth quarter.

    * Quinvaxem: The Korea Food and Drug Administration (KFDA) awarded licensure to Quinvaxem(TM), a fully liquid pentavalent vaccine co-developed with Chiron Corporation, in March 2006. Crucell has started production of the vaccine in Korea and first shipments will be made once pre-qualification is received from the WHO.

    * Divestments: Crucell concluded the sale of Rhein Biotech GmbH and veterinary pharmaceuticals company Dr. E. Gräub AG. These divestments enabled Crucell to align its portfolio of activities with its strategic priorities. Total proceeds amounted to €15.4 million.

    * Avian influenza vaccine clinical trial: Crucell announced the start of a clinical trial, performed in collaboration with the University of Leicester, UK, testing three types of vaccines against the H9N2 avian influenza virus in humans. The trial involves the vaccination of 560 healthy adults, and will allow Crucell to choose the best vaccine modality for further clinical studies with pandemic flu vaccines. First results of the study are expected by the end of 2006.

    * Patent infringement: Crucell settled its patent infringement proceedings against CEVEC Pharmaceuticals GmbH. The final claim in the case was withdrawn following CEVEC's commitment not to use its cell bank in any way that would constitute further infringement of Crucell's European PER.C6?patent.

    * STAR(TM) Technology: Crucell signed a non-exclusive STAR(TM) research license agreement with Cambridge, Massachusetts-based Millennium Pharmaceuticals Corporation.

    * PER.C6?Licensing: Crucell secured new PER.C6?licensing deals with Upstate USA, BIOA&D and Immuno-Biological Laboratories during the second quarter.

    * PER.C6?R&D Center: Crucell and technology partner DSM Biologics announced the establishment of a new PER.C6?R&D Center in Cambridge, Massachusetts, and the appointment of Dr Marco Cacciuttolo as CEO. Operations are expected to commence by the end of 2006.

    * Supervisory Board: Mr. Pieter Strijkert, chairman of Crucell's Supervisory Board since the Company's incorporation, stepped down at the Annual General Meeting of Shareholders on June 2, 2006. He was succeeded by the vice-chairman of the Supervisory Board, Mr. Jan Oosterveld.

    * Suspension of Aerugen?clinical development: On July 18, 2006, the Company announced the suspension of the clinical development program for Aerugen? a vaccine for the prevention of Pseudomonas aeruginosa infection.


    Details of the Financial Results First Half-Year

    Revenues and Other Operating Income
    Revenues for the first half-year of 2006 were €30.6 million, compared to €13.4 million in the same period last year. Revenues consist of product sales, license revenues and service fees. Revenues in 2006 represent product sales from Berna from the moment of acquisition at February 22, 2006; license revenues and service fees do not include sales from Berna and are therefore included for six months. Product revenues amount to €21.5 million, concentrated in pediatric and travel vaccines. Product revenues are seasonal and have historically been concentrated in the second half of the year. This is due to seasonal sales of influenza vaccine, and the projected sales of the new Quinvaxem(TM) pediatric vaccine. Comparable product sales from Berna in the first half-year 2006 were up 9% over same period last year.

    License revenues were €4.6 million, a decrease of €3.7 million over last year. Last year's license revenues included a €2 million milestone and a significant €2 million up-front fee from a partner. License revenue consisted of initial payments from new contracts as well as annual and other payments on existing contracts. Service fees amount to €4.5 million, compared to €5.1 million last year, which represents a slight decrease in chargeable development activities. Service fees represent revenues for product development activities performed under contracts with partners and licensees.

    Other Operating income was €4.8 million, compared to €2.6 million in the same period last year. Other operating income consists of government grants, which increased slightly to €3.0 million, and other income of €1.8 million.

    Cost of Goods Sold
    Cost of goods sold for the first six months of 2006 amounted to €27.4 million, €24.2 million of which represents product costs and the remainder of €3.2 million represents costs of service activities. The €24.2 million in product costs is relatively high since it includes a €6.4 million inventory purchase price allocation charge. The remaining step-up in inventory on June 30, 2006, as a result of the purchase price allocation, amounts to €11 million, which will be charged to cost of goods sold in future accounting periods.
  6. [verwijderd] 29 augustus 2006 08:10
    Crucell Announces Second Quarter 2006 Results 2/2Source: cws.huginonline.com/C/132631/PR/20060...
    PDF: hugin.info/132631/R/1071967/183209.pdf

    Expenses
    Total expenses consist of research and development (R&D) expenses and selling, general and administrative (SG&A) expenses. Total R&D and SG&A expenses were €48.6 for the first six months of 2006. That represents a €27.1 million increase over the same period last year. The difference is primarily attributable to combining activities of Crucell and Berna since acquisition.

    R&D expenses amounted to €29.8 million, which represents a €16.3 million increase over the first half of 2005. Berna clinical programs accounted for a €10.6 million increase in R&D costs in the first six months of 2006. Amortization as a result of the purchase price allocation added €2.1 million in expenses. In addition, costs for clinical development in Leiden for Rabies, West-Nile and Influenza clinical programs added €3.6 million in development costs over same period last year.

    SG&A expenses for the first half-year 2006 were €18.8 million and represent an increase of €10.8 million over the first half-year of 2005. Of the increase, €3.5 million represents the addition of the Berna G&A costs to the organization; €4.8 million represents sales & marketing expenses; and €2.5 million represents integration costs, like Sarbanes-Oxley implementation and various advisory costs.

    Net Loss
    The Company reported a net loss attributable to equity holders of the parent for the first half-year 2006 of €40.4 million, or €0.75 net loss per share.

    Minority interests of €0.5 million represent the share in results of minority shareholders in Berna Biotech AG as well as in Rhein Biotech NV, which is listed at the Frankfurt Exchange (FWB).

    Cash Flow and Cash Position
    Cash and cash equivalents increased by €65.9 million in the first six months of 2006 up to an amount of €177.7 million. The net increase is a result of the cash acquired in the acquisition. During the second quarter, cash deposits of €13.0 million were re-classified as restricted cash and serve as collateral for company mortgages and financial leases. These deposits are included on the balance sheet as other financial assets.

    Net cash used in operating activities in the first six months of 2006 was €24.1 million. Changes in working capital for the acquired company reflect changes in current assets and current liability balances since the date of acquisition.

    Cash from investing activities amounted to €79.3 million. This includes cash acquired in the acquisition of €76.9 million. €9.0 million was used to pay acquisition transaction costs. Proceeds from financial assets include €15.4 million of proceeds from divested assets, Rhein Biotech GmbH and Dr. E. Gräub AG., received in the second quarter. Proceeds from financial assets also include €17.9 million of deposits for which the maturity has decreased to less than 3 months in the second quarter, resulting in a reclassification to cash and cash equivalents.

    Net cash from financing activities was €11.0 million, of which €7.9 million represents an increase in mortgage loans and leasing liabilities. The Company has entered and intends to enter into financial leases to finance investment in property, plant and equipment, the effect of which will be to reduce cash outflow in the year the investment takes place. In the first six months the Company received €3.4 million from the issuance of ordinary shares for employee stock options exercised.

    Balance Sheet
    Total equity amounts to €464.3 million, of which €11.2 million represents minority interests. A total of 59 million ordinary shares were issued and outstanding on June 30, 2006.

    Inventories increased €12.1 million during the second quarter to €62.7 million by June 30, 2006. The increase in inventory is due to purchase of materials for influenza vaccine production in the second half of the year, as well as stock of intermediate and finished goods of Quinvaxem(TM) vaccine.

    Short-term financial assets decreased over the second quarter due to a reclassification of €17.9 million of deposits to cash and cash equivalents, since these deposits now have a maturity date of less than 3 months.

    Intangible assets amount to €116.2 million and represent acquired in-process R&D; patents and trademarks; and value of customer and supplier relationships. The purchase price allocation has been further updated during the second quarter and is expected to be finalized before year-end.

    Investments in Joint venture represent investment in Pevion. The Company's investment in Galapagos NV is classified under "Other financial assets."

    Reconciliation IFRS to US GAAP
    Shareholders equity under US GAAP is €413.4 million, €50.9 million lower than under IFRS. This is primarily due to the different method to determine the Berna acquisition price and write-off of in-process R&D of €61.8 million required under USGAAP.

    Net loss under US GAAP for the six months ended June 30, 2006, is €102.4 million versus a loss of €40.9 million under IFRS. The difference is mainly due to the write-off of in-process R&D under US GAAP as well as some other minor differences.

    Outlook
    The Company maintains its revenue outlook, including other operating income, for 2006 in the €130 to €150 million range, which is dependent on obtaining WHO pre-qualification of the Company's Quinvaxem(TM) vaccine.

    2006 will be a year of integration, affecting cash used in operations. Net of integration, one-time transaction costs, investment in plant and equipment and other proceeds from divestitures, the total decrease in cash over 2006 is expected to be in the €33 million to €38 million range. The Company expects to achieve operational cash break-even in 2007.
  10. [verwijderd] 29 augustus 2006 08:17
    quote:

    m van mour schreef:

    Wat zal deze dag ons brengen?
    Ik denk een sterke daling, volgens mij is het wachten op de WHO en kunnen we dan pas zien wat er mogelijk is met Crucell.

    mvm
    Kortzichtigheid ten top, maar wellicht de typische belegger? Alsof WHO alles is, zie ook eerdere draadjes. Gewoon afwachten, de zekerheid is er en de productie is er klaar voor.

    Wachten op het startschot en gelijk verkopen, of dat nu vandaag of morgen is of misschien volgende maand. Dat zal ze bij Crucell denk ik bar weinig uitmaken.

    Jammer alleen dat er verwachtingen zijn gewekt, altijd lastig voorspellen in deze sector en heb de voorspellingen altijd afgekeurd. Wellicht op de conference call ( www.companywebcast.nl/webcast//player... ) vandaag meer.
  20. [verwijderd] 29 augustus 2006 08:35
    quote:

    Hans Igor schreef:

    [quote=wilb52]
    Eerst de spike naar 14.75!
    Daarna sluiten op 4-day-high!

    sammie
    [/quote]
    Je zou wel weer eens helemaal gelijk kunnen krijgen, Sammie. Er is 1 partij aan het kloten, maar er zullen er toch ook zijn die dit koopje niet laten lopen.
    Gr.
    Hans Igor
    Go Grand-Cru-cell!!!

    En ook Hans heeft volgens mij helemaal gelijk, vroeger nog weleens onder de indruk van de grapjassen in het boekje voorbeurs. Maar we gaan gewoon redelijk openen en een volatiel dagje tegemoet.

    Als altijd zijn (helaas) de analisten meningen van belang. Zo ook de conference call, wat word er gezegd, beloofd en wellicht zelfs teruggenomen...
255 Posts
Pagina: 1 2 3 4 5 6 ... 13 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
UMG 25,940 +1,72 +7,10%
Basic-Fit 22,760 +0,88 +4,02%
DSM FIRMENICH AG 100,900 +3,78 +3,89%
WDP 20,320 +0,58 +2,94%
Air France-KLM 7,652 +0,22 +2,93%
AMG Critical Materials N.V. 13,570 +0,37 +2,80%
IMCD 148,700 +3,70 +2,55%
UNILEVER PLC 55,260 +1,30 +2,41%
Fagron 18,960 +0,42 +2,27%
Accsys 0,549 +0,01 +2,23%
VASTNED 28,400 +0,60 +2,16%
KPN 3,593 +0,07 +2,02%
Sligro 10,840 +0,20 +1,88%
NSI 19,740 +0,32 +1,65%
Flow Traders 23,680 +0,36 +1,54%
Heineken 67,340 +1,00 +1,51%
Ahold Delhaize 33,920 +0,48 +1,44%
Wereldhave 14,240 +0,20 +1,42%
CTP 15,780 +0,22 +1,41%
Philips Koninklijke 25,970 +0,36 +1,41%
ASR Nederland 47,330 +0,60 +1,28%
ACOMO 17,800 +0,18 +1,02%
Eurocommercial Properties 22,950 +0,20 +0,88%
JDE PEET'S 16,500 +0,14 +0,86%
PostNL 0,944 +0,01 +0,80%
Wolters Kluwer 170,650 +1,30 +0,77%
Aegon 6,288 +0,04 +0,70%
NN Group 43,190 +0,29 +0,68%
INPOST 15,770 +0,10 +0,64%
SBM Offshore 17,930 +0,11 +0,62%
Kendrion 10,040 +0,06 +0,60%
AMX 835,20 +3,87 +0,47%
Corbion 22,740 +0,08 +0,35%
ArcelorMittal 23,770 +0,06 +0,25%
RANDSTAD NV 42,110 +0,09 +0,21%
ForFarmers 3,290 +0,00 +0,15%
ALLFUNDS GROUP 4,978 +0,00 +0,08%
ING 16,026 +0,01 +0,04%
ABN AMRO BANK N.V. 16,040 +0,00 +0,03%
AALBERTS NV 33,920 0,00 0,00%
Aperam 25,760 0,00 0,00%
B&S Group SA 4,200 0,00 0,00%
RELX 46,680 0,00 0,00%
Van Lanschot Kempen NV 46,400 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
ASMI 536,000 -73,00 -11,99%
BESI 125,550 -10,35 -7,62%
ASML 650,700 -50,00 -7,14%
Brunel 9,290 -0,28 -2,93%
NX FILTRATION 2,875 -0,09 -2,87%
EBUSCO HOLDING 0,915 -0,02 -2,32%
THEON INTERNAT 13,500 -0,30 -2,17%
Alfen N.V. 12,310 -0,26 -2,11%
TKH 34,440 -0,74 -2,10%
Sif Holding 11,760 -0,24 -2,00%
Avantium 1,732 -0,03 -1,93%
TomTom 5,275 -0,09 -1,77%
BAM 4,034 -0,06 -1,56%
FASTNED 20,300 -0,30 -1,46%
Pharming 0,858 -0,01 -1,38%
Fugro 15,440 -0,20 -1,28%
JUST EAT TAKEAWAY 11,685 -0,14 -1,18%
SIGNIFY NV 22,400 -0,26 -1,15%
SHELL PLC 30,930 -0,36 -1,13%
ADYEN NV 1.508,200 -12,20 -0,80%
AEX 894,18 -7,15 -0,79%
Arcadis 54,800 -0,30 -0,54%
CM.COM 5,780 -0,02 -0,34%
Nedap N.V. 58,000 -0,20 -0,34%
Akzo Nobel 60,380 -0,20 -0,33%
ASCX 1.238,71 -4,09 -0,33%
PROSUS 35,340 -0,11 -0,32%
OCI 11,035 -0,04 -0,32%
AZERION 1,576 0,00 -0,25%
EXOR NV 89,850 -0,20 -0,22%
HEIJMANS KON 29,450 -0,05 -0,17%
RENEWI 9,530 -0,01 -0,10%
Vopak 43,420 -0,04 -0,09%
Galapagos 22,680 -0,02 -0,09%
vlag naam koers verschil relatief verschil
AEX 894,18 -7,15 -0,79%
AEX GR 3.511,25 -24,07 -0,68%
Germany40^ 21.279,60 -115,33 -0,54%
FTSE 100 8.511,62 +9,27 +0,11%
Europe50^ 5.187,85 -31,52 -0,60%
US30^ 44.357,30 -40,10 -0,09%
Nasd100^ 21.085,50 -686,60 -3,15%
US500^ 5.986,19 -113,50 -1,86%
Japan225^ 39.001,70 -1.478,10 -3,65%
VD-NEW 14,76 +0,11 +0,78%
#/^ Index indications calculated real time, zie disclaimer